Sequencing Reagent Market By Reagent Type (Library Kits, Template Kits, Control Kits, Sequencing Kits, Others), By Technology (Sanger Sequencing, Next-Generation Sequencing, Third Generation Sequencing), By Application (Oncology, Reproductive Health, Clinical Investigation, Agrigenomics & Forensics and Others), By End-User (Academic Research, Clinical Research, Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Others), By Region - Market Trends, Analysis, and Forecast till 2029

Sequencing Reagents Market size was valued at USD 5.1 Billion in 2019 and is expected to register a CAGR of 13.8% over the forecast period.

The market is benefitted by constant developments in sequencing technologies to provide higher throughput data for large-scale genomic research. The development of novel technologies, such as Nanopore and Single-Molecule Real-Time (SMRT) sequencing, for efficient and cost-effective preparation of sequencing libraries, enable researchers to sequence the entire genome within a short period at a lower cost. This, coupled with the availability of new commercial kits providing reagents for specific sequencing applications, drives the market progression. Streamlining the workflow and automation have gradually reduced the overall time of the library preparation step. Besides, tagmentation during library preparation combines adaptor ligation and genome fragmentation into a single step. Incorporation of this technique into existing sequencing procedures simplifies workflow, reduces cost, and improves data quality.  The presence of supportive government programs has augmented the growth of genome sequencing in identifying the genomic variations associated with human diseases. For instance, in December 2018, NHS England, in partnership with Genomics England, sequenced 100,000 whole genomes from NHS patients to uncover new diagnoses and treatment for patients with cancer and rare diseases.

Increasing Clinical Application of Genome Sequencing (GS)

After the introduction of GS technologies in 2005, they have had an incredible influence on genomic research and clinical applications. Generation sequencing, currently, has its application in the diagnosis of a variety of illnesses, such as cancer, hematological disorders, neurology, psychiatry, dysmorphology, vision and hearing impairment, cardiology, and pharmacogenomics. It is also used as a tool for noninvasive prenatal tests. Genome Sequencing technologies have been used for standard sequencing applications, like genome sequencing, and for novel applications that were previously unexplored by using Sanger sequencing. Applications include whole genome and transcriptome sequencing, metagenomic characterization of microbial types in environmental and clinical specimens, explanation of DNA binding sites for chromatin and regulatory proteins, and targeted re-sequencing of specific sites in the human genome, identified by linkage analyses.

Growing Preference Toward Personalized Medicines And Early Disease Diagnosis

Technological advancements in the field of medicine, especially in the tools, such as the informatics, have been happening at a rapid rate, which has led to the development of personalized medicine. There are a huge number of applications of generation sequencing in personalized medicine. The advantages of personalized medicine is that, they have been useful in designing the treatment based on the molecular alterations. Its use has been most advanced around the treatment of oncological diseases to target the genetic alterations.

Lack of Skilled Technicians for GS Data Analysis

The lesser number of skilled professionals for the analysis and data interpretations of NGS data, along with the lack of knowledge of new informatics tools among medical professionals, is likely to limit the growth of the sequencing reagents market. Additionally, high cost involved in the maintenance and security of informatics tools is likely to contribute to the same.

Sequencing Reagent Market is segmented based on Reagent Type, Technology, Application, End-User and region.

Sequencing Reagent Market is segmented based on Reagent Type as Library Kits, Template Kits, Control Kits, Sequencing Kits, Others. On the basis of Technology market is segmented into Sanger Sequencing, Next-Generation Sequencing, Third Generation Sequencing. On the basis of Application market is segmented into Oncology, Reproductive Health, Clinical Investigation, Agrigenomics & Forensics and Others, On the basis of End-User market is segmented into Academic Research, Clinical Research, Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Others. On the basis of Region market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East & Africa.

Regional Insights:

On region the Sequencing Reagent Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The North American sequencing reagents market accounted for a revenue share of 46.9% in 2019 and was valued at USD 2,372.2 million, and is projected to reach USD 6,741.3 million by 2027, growing at a CAGR of 14.0% from 2020 to 2027.

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2019 to 2029. For the purpose of this study, has segmented the Global Small Payment Institution Money Transfer Market report based on product, site of collection, application, and region.

Global Sequencing Reagents Market, By Region:

• North America
  • Middle East & Africa
    • • GCC
      • Israel
      • South Africa
      • Rest of Middle East & Africa
  • Latin America
    • • Brazil
      • Mexico
      • Rest of Latin America
  • Asia Pacific
    • • China
      • India
      • Japan
      • South Korea
      • Rest of Asia Pacific
  • Europe
    • • Germany
      • UK
      • France
      • Russia
      • Italy
      • Rest of Europe
  • • U.S.
    • Canada

The key players operating in the sequencing reagent Market includes QIAGEN, Pacific Biosciences of California, Inc., Thermo Fisher Scientific, Inc., Fluidigm Corporation, ArcherDX, Inc., BGI, Illumina, Inc., Agilent Technologies, Inc., Oxford Nanopore Technologies and Hoffmann-La Roche Ltd. Over the recent years, technologies, like Illumina/Solexa, ABI/SOLiD, 454/Roche, and Helicos, have provided unique prospects for high-throughput functional genomic research. After the introduction of GS technologies in 2005, they have had an incredible influence on the genomic research. In the last few years, several companies are investing in the research and development of GS informatics. For example, Illumina has acquired the Edico Genome in 2018, to accelerate genomic data analysis and improve its informatics tools. By this acquisition the Illumina Company will be benefited in the research of GS informatics. Similarly, few other companies are also acquired or made partnership with other companies

• QIAGEN
• Pacific Biosciences of California, Inc.
• Thermo Fisher Scientific, Inc.
• Fluidigm Corporation
• ArcherDX, Inc.
• BGI
• Illumina, Inc.
• Oxford Nanopore Technologies
• Hoffmann-La Roche Ltd.